M3258, a highly selective and orally bioavailable LMP7 inhibitor, was recently described to exhibit strong antitumor activity in preclinical models of MM [13,15], as well as a more favorable non-clinical safety profile in rats and dogs than the safety profile described for pan-PIs [14]. This evidence concerns the gene PSMB8 and Miyoshi myopathy.